01Overview 02Daily Brief 03Live 04Congress 05Corporate Insiders 06Government Money 07Political Influence 08Institutions 09Washington Network 10Follow the Power 11Disclosure Clock 12AI Investigator 13Watchlist

Convergence INSIDER Alpha Signal ledger Historical Replay Robinhood Chain Proof Trading Token Methodology Match review Launch readiness

Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…

Overview Daily Brief Live Congress Corporate Insiders Government Money Political Influence Institutions Washington Network Follow the Power Disclosure Clock AI Investigator Watchlist Convergence INSIDER Alpha Signal ledger Historical Replay Robinhood Chain Proof Trading Token Methodology Match review Launch readiness

01Overview 02Daily Brief 03Live 04Congress 05Corporate Insiders 06Government Money 07Political Influence 08Institutions 09Washington Network 10Follow the Power 11Disclosure Clock 12AI Investigator 13Watchlist

Convergence INSIDER Alpha Signal ledger Historical Replay Robinhood Chain Proof Trading Token Methodology Match review Launch readiness

Overview Daily Brief Live Congress Corporate Insiders Government Money Political Influence Institutions Washington Network Follow the Power Disclosure Clock AI Investigator Watchlist Convergence INSIDER Alpha Signal ledger Historical Replay Robinhood Chain Proof Trading Token Methodology Match review Launch readiness

Data sources

SEC FORM 43h ago

HOUSE PTR3h ago

SEC 13F3h ago

ROBINHOOD CHAIN3h ago

Public company

IMMXImmix Biopharma, Inc.

CIK 0001873835

EDGAR filings Open in network

Disclosed transactions0

Buys / sells0 / 0

Max Insider Score—

Connections4with evidence

IMMX · disclosed activity on price

Disclosed transactions

No records

No transactions recorded for this profile.

Verified connections

In industryevidence
Pharmaceuticals, devices & health servicesSEC SIC 2834 · Pharmaceutical Preparations · Nov 4, 2026
← Lobbied forevidence
AXADVOCACY GOVERNMENT RELATIONSLDA Q2 2026 second quarter · Health issues · Aug 26, 2026
← Lobbied forevidence
TARPLIN, DOWNS & YOUNG, LLCLDA Q2 2026 second quarter · Health issues · Aug 26, 2026
← Lobbied forevidence
CONTINENTAL STRATEGY, LLCLDA Q2 2026 second quarter · MED · Aug 26, 2026

Lobbying

$215K reported · de-duplicated

2026 Q2 $145K via firms2026 Q1 $70K via firms

TARPLIN, DOWNS & YOUNG, LLC—2026 Q1 · posted Aug 26, 2026 · Health issues
AXADVOCACY GOVERNMENT RELATIONS—2026 Q2 · posted Aug 26, 2026 · Health issues
CONTINENTAL STRATEGY, LLC$50K2026 Q1 · posted Aug 26, 2026 ·
TARPLIN, DOWNS & YOUNG, LLC$20K2026 Q1 · posted Aug 26, 2026 · Health issues
AXADVOCACY GOVERNMENT RELATIONS$20K2026 Q2 · posted Aug 26, 2026 · Health issues
CONTINENTAL STRATEGY, LLC$105K2026 Q2 · posted Aug 26, 2026 · MED
CONTINENTAL STRATEGY, LLC—2026 Q1 · posted Aug 26, 2026 · MED
TARPLIN, DOWNS & YOUNG, LLC$20K2026 Q2 · posted Aug 26, 2026 · Health issues

Connected PAC contributions

FEC · direct to members

No contributions from a PAC connected to this company.